Explorez tous les épisodes du podcast The Lancet Rheumatology in conversation with

In this month’s episode we discuss childhood-onset Sjögren’s disease-a rare and under-researched rheumatic condition.  Lack of robust clinical and immunological characterisation of this condition alongside assessment of its impact on quality of life has significantly hampered progress in the delivery of high-quality research and evidence-based recommendations for care.  There are currently no studies following up children and young people with childhood-onset Sjögren's disease as they move into adulthood and there remains a clear knowledge gap surrounding the natural course and long-term outcomes of childhood-onset Sjögren's disease. Professor Coziana Cuirtin from the Centre for Adolescent Rheumatology at the University College London discusses the long-term outcomes of patients with childhood-onset Sjögren’s disease. We also discuss barriers and facilitators to recruiting these patients, the current management strategies available and what’s next for childhood-onset Sjögren’s disease research.

Click here to read the full article: https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(25)00283-8/fulltext

-----------------------------------------------

Medical imaging and theranostics are revolutionising how we diagnose, treat, and understand disease. To meet this moment, The Lancet group is happy to announce the launch of, The Lancet Medical Imaging and Theranostics. 

You can visit https://www.thelancet.com/medical-imaging-theranostics to learn more.

Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

This months episode covers Hemophagocytic lymphohistiocytosis, or HLH, a rare, life-threatening disorder characterised by dysregulated immune activity resulting in systemic inflammation, tissue damage and multiorgan failure which affects both children and adults. The annual prevalence of HLH in England is around 2 per million people in the adult population, with an overall 1-year survival rate of around 50% and similar rates have also been reported in other countries across the world. However, as most studies of HLH prevalence primarily focus on single nations and specific subpopulations, epidemiological data on global incidence and mortality rates are scarce. Dr Fiona Pearce and Dr Rachel Tattersall discuss their recent publication in The Lancet Rheumatology which looked at mortality rates of HLH across Europe, we also discuss what manifestations clinicians should be looking out for and what’s next for HLH research.

Click here to read the full article: https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(25)00292-9/fulltext

Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

This is the third and final episode of our mini-series on cell-based therapies in rheumatology, with Professor Fabian Müller and Dr Melanie Hagen from the Erlangen University, Germany. We discuss their recently published a study on a newly discovered toxicity of CD-19 targeting CAR T-cell therapy in patients with autoimmune disease, as well as the recent successes of CAR T-cell therapy, ideal patient selection, and future directions.

Read the full article:

https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(25)00091-8/fulltext?dgcid=buzzsprout_icw_podcast_Jun_25_lanrhe

Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

This is the second episode of a mini series on cell-based therapies in rheumatology, with Prof. Dominique Farge discussing the use of allogeneic umbilical cord-derived mesenchymal stromal cells (MSCs) as treatment for systemic lupus erythematosus (SLE). 

We cover the limited options currently available for people with severe or refractory SLE, the complexities in using MSCs, Prof. Farge's recent study results, and how these results fit in with the evidence available, as well as the future for this area of research. 

You can find the study here:

https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(24)00298-4/fulltext?dgcid=buzzsprout_icw_podcast_25-04-25_lanrhe

Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

The first episode of a mini series on cell-based therapies in rheumatology, with Prof Rebecca Marsh and Grant Schulert discussing the use of allogeneic haematopoietic stem-cell transplantation for children with refractory systemic juvenile idiopathic arthritis and associated lung disease.

Read the full article:

https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(24)00275-3/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanrhe

Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

Dr Bryant England discusses the use of TNF-inhibitor versus non-TNF inhibitor biological or targeted synthetic DMARDs for treatment of rheumatoid arthritis-associated ILD, and the effects on survival and respiratory hospitalisation outcomes.

Read the full article:

https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(24)00265-0/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanrhe

Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

Dr Brooke Conley and Associate Professor Ivan Lin discuss their recent study on integrating evidence from lived experience of Aboriginal people and clinical practice guidelines to develop arthritis educational resources.

Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

Dr Mark Russell and Sherry Yang discuss the factors influencing initiation of biologics in underserved populations with rheumatoid arthritis in the UK, how historical redlining and present-day racialised economic segregation affects health-care utilisation of adults with rheumatic diseases in the USA, and health inequities seen in rheumatology more broadly. Read the full article: https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(24)00221-2/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanrhe

Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

Dr Quirine Dumoulin discusses the efficacy of a 1-year course of methotrexate on the development of rheumatoid arthritis in ACPA-negative people with clinically suspect arthralgia and predicted increased risk of rheumatoid arthritis. Read the full article: https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(24)00196-6?dgcid=buzzsprout_icw_podcast_generic_lanrhe

Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

Dr Sebastian Sattui discusses the effects of age and frailty on the risks of end-stage renal disease, death, and severe infection in older adults with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Read the full article: https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(24)00193-0/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanrhe

Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

To celebrate 5 years of The Lancet Rheumatology, international advisory board members Oliver Distler, Laura Coates, and David Liew discuss recent progress made, challenges to overcome, and future directions in rheumatology. Read the associated Editorial: https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(24)00245-5/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanrhe

Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

Dr Karen Schreiber, Professor Ian Giles, and Professor Angela Tincani discuss the Series on Pregnancy and Rheumatic Diseases, including the use of DMARDs during pregnancy, study design and conduct, and outcomes for children born to mothers with rheumatic diseases. Read the Series: https://thelancet.com/series/pregnancy-rheumatic-diseases?dgcid=buzzsprout_icw_podcast_generic_lanrhe

Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

During this episode, Dr John Isaacs and Dr Josh Bennett from Newcastle University and the NIHR Newcastle Biomedical Research Centre, discuss sarcopenia - an age-related loss of muscle mass and strength. Sarcopenia is relatively common in rheumatoid arthritis, with a prevalence ranging from 4·5% to 44% of people with rheumatoid arthritis, depending on the definition of sarcopenia used. Rheumatoid sarcopenia increases the risk of fall, fractures, disability, and hospitalisation. Therefore, prevention and management is important, especially in older patients. We discuss the how and why sarcopenia arises and how it can be managed, as well as the recent publication of the RAMUS study, which looked at the skeletal muscle effects of JAK inhibitor tofacitinib in rheumatoid arthritis. The link to the Nature Rheumatology Review mentioned can also be found below. RAMUS study: https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(25)00184-5/fulltext Nature Rheumatology Review: https://www.nature.com/articles/s41584-023-00921-9

Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

Dr Maria Tektonidou discusses the results of a cross-sectional analysis of international data on cardiovascular risk factors in systemic lupus erythematosus.

Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

Dr Rosemary Hollick, University of Aberdeen, discusses a mixed-methods study on key health system components associated with improved outcomes to inform the re-configuration of services for adults with rare autoimmune rheumatic diseases.

Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

Editors Heather Van Epps and Anna Clark join guest hosts Lola Falasinnu, David Liew, and Puja Mehta to reflect on the progress of The Lancet Rheumatology and share their vision for the future. 

Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

Dr Shirin Heidari, Prof James Wason, Dr Karen Schreiber, and Prof Cheryl Barnabe join guest host Dr David Liew to discuss how sex and gender impact research design and reporting and improvements that can be made. Learn more: The Lancet Summit: Sex and gender in rheumatology

Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

Drs. Randy Cron and Chandrika Bhat join guest host Dr Puja Mehta to discuss the opportunities and challenges of cross-speciality research. 

Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

Prof Michael Weisman joins guest host Dr Lola Falasinnu to discuss the challenges of conducting clinical trials in rheumatology and recent developments in trial design.

Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

Prof Catherine Nelson-Piercy and Dr Lizemarie Wium join guest host Dr Puja Mehta to discuss the importance and challenges of obstetric medicine in rheumatic diseases. 

Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

Greta Lindenmayer, Stephen Brady, and Onika Paolucci join guest host David Liew to discuss specialist considerations for the care of Australian Aboriginal patients with lupus.

Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

Clinical Realities: Duncan Porter and Shahir Hamdulay discuss the challenges facing rheumatology care in the UK in 2022, and what's needed to improve care in the coming years. 

Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

Dr. Thomas Bush joins guest host Dr. Lola Falasinnu to discuss climate change and the potential adverse health effects of climate hazards for patients with rheumatic diseases. 

Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

This month's episode covers Sjögren’s disease—an autoimmune condition that primarily affects areas of the body that produce fluids, such as tears and saliva. The cause of the disease isn’t understood. Currently there are no licensed drugs to treat the disease, but phase 2 clinical trials have reported encouraging results, and phase 3 trials are underway. Dr Samuel Bitoun, from the University of Paris-Saclay and APHP, discusses how Sjögren’s disease is currently classified, the challenges of using such classification, and how AI and deep learning could potentially contribute to this area, which is the focus of his recent study published in The Lancet Rheumatology, which aimed to train a neural network model to perform focus score classification and identify new histological patterns associated with this disease.

Click here to read the full article: https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(25)00181-X/fulltext

Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

Dr. Coziana Ciurtin and Dr. Kate Webb join guest host Dr. Puja Mehta to discuss the challenges and opportunities involved in transitional care for adolescent patients with rheumatic diseases as they progress to adulthood. Read the profile of Puja: Puja Mehta: taking the path untrodden

Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

Dr. Dzifa Dey joins guest host Dr. David Liew to discuss innovations in providing specialist rheumatology care and patient education in Ghana, and how her experiences in Africa could help inform development of rheumatology care in other low-resource settings.

Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

Dr. Eric Peters and Prof. Jinoos Yazdani join Editor-in-Chief Heather Van Epps to discuss the challenges of providing specialist rheumatology care to undocumented immigrants in the USA. 

Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

In today's episode, Sophie discusses psoriatic arthritis with Dr Ryan Hum from The University of Manchester. Psoriatic arthritis affects between 0.1% and 1% of the general population globally, and appears to be more prevalent in certain regions. It affects men and women equally and typically appears between the ages of 30 and 55 years. Psoriatic arthritis tends to be more common in people with psoriasis affecting around 20% of individuals, but estimates can depend on the inclusion criteria studies use. We touch on the pathogenesis of psoriatic arthritis and how it might manifest in a patient, as well as the contribution of synovial inflammation and how research into this topic contributes to our understanding of the disease. We also discuss the reasons psoriatic arthritis research is in the early stages when compared to rheumatoid arthritis. 

The Review discussed can be found here: https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(25)00231-0/fulltext

Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

In this episode, we’re tackling a condition that affects over 374 million people worldwide—knee osteoarthritis (OA). As the most common site of OA, knee OA is a leading cause of disability and accounts for more than 12 million disability-adjusted life years globally. With prevalence rising steadily due to aging populations and increasing obesity rates, the burden of knee OA is projected to climb even further in the coming decades. We speak with the lead author of a new study published in The Lancet Rheumatology, Dr Scott Uhlrich, from the University of Utah. The study offers fresh insights into the management of knee OA through personalised gait retraining. We’ll explore the study’s design, its clinical implications, and what the future might hold for patients with knee OA.

Read the full article:

https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(25)00151-1?dgcid=buzzsprout_icw_podcast_September_25_lanrhe

Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

In this episode, we'll be discussing an issue that affects millions of people globally - low back pain. We will find out why the burden of low back pain is so high, why current management is so ineffective, what we can do from a research and care perspective to improve outcomes for patients, and whether prevention is the way forward. 

We’ll also discuss a couple of papers that have been recently published in The Lancet Rheumatology looking at longer-term treatment options for low back pain, and how useful they are.

Read the Systematic Review:

https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(25)00064-5/abstract?dgcid=buzzsprout_icw_podcast_August_25_lanrhe

Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

In this episode Professor Vibeke Strand discusses polymyalgia rheumatica (or PMR), a common inflammatory rheumatic disease that significantly impairs patients’ quality of life, causing fatigue, pain, and physical disability, especially in relapsing cases that often require long-term glucocorticoid treatment. However, these treatments come with considerable side effects, and many patients do not respond to treatment.

We also cover her recent publication, which explores the patient reported outcomes of a trial using sarilumab, a monoclonal antibody targeting the inflammatory cytokine IL-6, which has now been approved for treatment of PMR in the USA.

Read the full article:

https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(25)00041-4/fulltext?dgcid=buzzsprout_icw_podcast_July_25_lanrhe

Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

This is a joint podcast between The Lancet Rheumatology and The Lancet Regional Health - Western Pacific with Prof Xue Li. Biologics have become a mainstay of treatment in Rheumatology in Western populations, but in many parts of Asia, especially lower-and-middle-income countries, there remains substantial inequity in access due to differences in availability and affordability. In this episode, we explore the factors that may have delayed the popularisation of biologics in Asia, any recent policy changes and the role of biosimilars in this landscape.

Read the full article:

https://www.thelancet.com/journals/lanwpc/article/PIIS2666-6065(22)00121-3/fulltext?dgcid=buzzsprout_icw_podcast_June_25_lanwpc

Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

In this podcast, Professor Savic talks about his recent publication that looks at treatment outcomes in patients with VEXAS syndrome, as well as what clinicians should look out for in patients (red flags), and future priorities for research. VEXAS syndrome (short for Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome) was first described in 2020. It’s a rare, and often-life threatening, inflammatory condition primarily affecting men. It's caused by a mutation in the UBA1 gene, leading to systemic inflammation and progressive bone marrow failure. The condition can manifest with a variety of symptoms, including fevers, fatigue, rashes, and joint pain, and can affect various organs and tissues.

Read the full article:

https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(25)00034-7/fulltext?dgcid=buzzsprout_icw_podcast_June_25_lanrhe

Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

In August’s episode, Dr Mrinalini Dey from the Centre for Rheumatic Diseases at King’s College London discusses her recent publication on the association between health literacy and outcomes in people with inflammatory arthritis in England. Health literacy—the ability to access, understand, evaluate, and use health information and services in ways that promote and maintain good health and wellbeing—is increasingly recognised as a key factor in promoting health and managing chronic diseases. The World Health Organization has identified health literacy as central to the prevention and control of non-communicable diseases, such as rheumatic and musculoskeletal conditions. As a potentially modifiable social determinant of health, health literacy can influence how patients experience and manage disease. Yet, its relationship with clinical outcomes, mental health, work participation, and broader social factors in inflammatory arthritis remains poorly understood. We discuss the findings from Dr Dey’s large, national cohort study, how we can improve health literacy disparities in patients, and what should be next on the research agenda to tackle this issue.

Click here to read the full article:

https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(26)00081-0/fulltext

In today’s episode Professor Eric Morand discusses the results of Cohort A and Cohort B of the WILLOW trial which investigated the efficacy and safety of enpatoran, a novel, oral small molecule inhibitor of Toll-like receptors 7 and 8 (TLR 7/8) in patients with cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE). The interferon pathway has been implicated in both CLE and SLE pathogenesis, however, the mechanism through which interferon expression is induced in lupus remains unknown. Targeting TLR 7/8 is of particular interest, as they are key drivers of interferon activation. Enpatoran has previously shown efficacy in early phase 1 trials of patients with CLE and SLE, with improvements in SLEDAI-2K and reduction in IFN-gene signatures with good safety profiles. We also highlight the differences in study design and endpoints of each cohort, compare and contrast enpatoran to currently approved therapies for SLE, anifrolumab and deucravacitinib, and finally, outline what the next research priority should be for patients with CLE and SLE.

Click here to read the full articles:  https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(25)00337-6/fulltext and https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00463-0/fulltext

In this month’s podcast, we explore Associate Professor Kragstrup’s recent proof-of-concept study which reports glucagon-like peptide-1 (GLP-1) concentrations and dipeptidyl peptidase-4 (DPP-4) activity in paired plasma and synovial fluid from patients with rheumatoid arthritis and spondyloarthritis and discuss whether there may be potential for intra-articular GLP-1 receptor agonist injections in these patients?

GLP-1 receptor agonists are gaining increasing attention in rheumatology due to their immunomodulatory and anti-inflammatory effects, highlighting their role as a potential therapeutic option for patients with rheumatic disease. Whether GLP-1 and DPP-4 (the key regulator of GLP-1) are present in synovial fluid of patients with rheumatic disease and to what extent remains to be seen. Understanding their interplay within the joint may provide more insight on whether GLP-1 receptor agonists could exert direct intra-articular effects in rheumatic disease. We also discuss limitations and barriers of investigating GLP-1 and DPP-4 and the next research priorities for determining the efficacy of GLP-1 receptor agonists in patients with rheumatic disease.

Click here to read the full article: https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(26)00074-3/fulltext

In this episode, Professor Dirk Foell from University Hospital Münster unpacks the findings from a recent Europe-wide survey examining trends in paediatric rheumatology care.

Despite significant scientific advances, delivering consistent, high-quality care for children with rheumatic and musculoskeletal diseases remains a challenge. Drawing on Professor Foell's recent Viewpoint, we discuss variation in paediatric rheumatology training pathways, subspecialty accreditation, and professional recognition across Europe, and how these disparities can impact workforce development and clinical care.

Click here to read the full article: https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(25)00378-9/fulltext

As part of The Lancet Rheumatology’s special issue on public and patient involvement in rheumatology, in this month’s episode, Aisling talks to Professor Jon Lampa about his recent publication on the patient-reported outcomes from the NORD-STAR trial.

The 2023 NORD-STAR trial was the first randomised trial to compare three different biological DMARDs, all in combination with methotrexate with active conventional treatment in patients with early rheumatoid arthritis. The study showed that after 48 weeks remission rates were higher in two of the three (Certolizumab pegol, abatacept, but not tocilizumab) biological DMARDs compared to active conventional treatment and that while radiographic progression was low, it was similar between groups. Providing an interesting insight into the management of patients with newly diagnosed rheumatoid arthritis.

Patient-reported outcomes are vital for measuring health, quality of life and treatment impact directly from the patient perspective–and now the data on how these treatments impact patient-reported outcomes is here. We also discuss the importance of reporting patient-reported outcomes in clinical trials, the benefits of including patients and people with lived experience in research and what the future of patient-reported outcome measures looks like.

Click here to read the full article: https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(26)00007-X/fulltext

Medical imaging and theranostics are revolutionising how we diagnose, treat, and understand disease. To meet this moment, The Lancet group is happy to announce the launch of, The Lancet Medical Imaging and Theranostics. 

You can visit https://www.thelancet.com/medical-imaging-theranostics to learn more.

Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv